Survival Associations of Timely Postoperative Radiotherapy Among Head and Neck Cancer High-Risk Subgroups

被引:0
|
作者
Velez, Lisa M. Velez [1 ]
Corpuz, Timothy V. [1 ]
Schwetschenau, Luke C. [1 ]
Mazul, Angela [2 ]
Massa, Sean T. [1 ]
机构
[1] St Louis Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63103 USA
[2] Washington Univ, Sch Med St Louis, Dept Otolaryngol Head & Neck Surg, St Louis, MO USA
来源
LARYNGOSCOPE | 2025年
关键词
head and neck cancer; postoperative radiotherapy; survival; SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; TREATMENT DELAYS; SURGERY; DISPARITIES; INITIATION; IMPACT; RACE;
D O I
10.1002/lary.32074
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
ObjectiveEffective implementation of timely postoperative radiation therapy (PORT) as a quality metric for head and neck squamous cell carcinoma (HNSCC) care may reduce survival disparities in subgroups with the highest risk of mortality-advanced stage and Black race. We sought to determine if the association between timely PORT and survival varies among clinical and demographic high-risk subgroups.MethodsIn this retrospective cohort study using the National Cancer Database 2004-2020, patients with HPV-negative HNSCC treated with surgery and PORT were identified. The association between PORT delay greater than 6 weeks with overall survival was assessed by Cox proportional hazards models with interaction effects for race, overall stage, and PORT delay.ResultsAmong 54,035 patients included in the study, 62% (33491) had PORT delays. Black patients were more likely to have PORT delays (aOR 1.19, 95% CI: 1.10-1.27). Timely PORT was only associated with improved survival for all stage I patients and White stage IV patients (predicted mortality risk 2.53, 95% CI: 2.34-2.74 versus 2.88, 95% CI: 2.67-3.09, referenced to White, stage I). After adjusting for covariates, timely PORT was estimated to be associated with inferior overall survival in Black patients with stage IV disease although with low precision (predicted mortality risk 3.24, 95% CI: 2.87-3.66, versus 2.71, 95% CI: 2.47-2.98, referenced to White, stage I).ConclusionTimely, guideline-adherent PORT may not reduce survival disparities in Black patients, especially those with advanced stage disease, suggesting other interventions are needed to address this disparity.Level of Evidence3.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Postoperative radiotherapy for head and neck cancer with single positive node
    Ampil, Federico L.
    Caldito, Gloria
    Nathan, Cherie-Ann
    Ghali, Ghali
    Baluna, Roxana
    Jones, Stephen
    JOURNAL OF RADIOTHERAPY IN PRACTICE, 2010, 9 (01) : 27 - 31
  • [42] POSTOPERATIVE RADIOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK-CANCER
    FRANCHIN, G
    DEPAOLI, A
    GOBITTI, C
    BOZ, G
    MINATEL, E
    RONCADIN, M
    ARCICASA, M
    BORTOLUS, R
    INNOCENTE, R
    TROVO, GM
    GRIGOLETTO, E
    TUMORI, 1989, 75 (01) : 47 - 52
  • [43] Randomized clinical trial on 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: focus on hemoglobin concentration
    Suwinski, R.
    Bankowska-Wozniak, M.
    Majewski, W.
    Idasiak, A.
    Maciejewski, A.
    Ziolkowska, E.
    Windorbska, W.
    Miszczyk, L.
    Skladowski, K.
    Maciejewski, B.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 : 94 - 95
  • [44] Delivery of Timely Adjuvant Radiation Among Veterans With Head and Neck Cancer
    Gulati, Jasmine
    Shah, Anuja
    Shah, Veranca
    Haupt, Thomas
    Walsh, Amanda
    Maxwell, Jessica H.
    OTO OPEN, 2025, 9 (01)
  • [45] POSTOPERATIVE CONCURRENT CHEMORADIATION FOR HIGH RISK HEAD & NECK SQUAMOUS CELL CANCER
    Antonadou, T.
    Paschalis, T.
    Silyvridou, A.
    Roumeliotis, D.
    Spyrakos, M.
    Dimakopoulou, V.
    Pantazis, D.
    Throuvalas, N.
    Bankousli, I.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S331 - S331
  • [46] Postoperative radiotherapy following mastectomy for high-risk breast cancer: a randomised trial
    Morgan, DAL
    Berridge, J
    Blamey, RW
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (08) : 1107 - 1110
  • [47] Postoperative concurrent chemo-radiotherapy with a modified cisplatin schedule in high-risk squamous-cell carcinoma of the head and neck (HNSCC)
    Schena, M.
    Rampino, M.
    Passeri, L.
    Barone, C.
    Grillo, R.
    Migliaccio, F.
    Pecorari, G.
    Cavalot, A.
    Garzino-Demo, R.
    Ciuffreda, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 338 - 338
  • [48] A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer
    Oosting, Sjoukje F.
    Chen, Tom W. W.
    Huang, Shao H.
    Wang, Lisa
    Waldron, John
    Gilbert, Ralph
    Goldstein, David
    Halmos, Gyorgy B.
    Witjes, Max J. H.
    Gietema, Jourik A.
    O'Sullivan, Brian
    Langendijk, Johannes A.
    Siu, Lillian L.
    Hansen, Aaron R.
    ORAL ONCOLOGY, 2016, 59 : 43 - 49
  • [49] Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score matched analysis
    Dou, Shengjin
    Wang, Xin
    Xiao, Ying
    Zhang, Lin
    Jiang, Wen
    Ye, Lulu
    Wang, Yu
    He, Yining
    Liu, Shengwen
    Li, Rongrong
    Zhu, Guopei
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2025, 53
  • [50] A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer
    Oosting, S. F.
    Chen, T. W. W.
    Huang, S. H. H.
    Wang, L.
    Waldron, J.
    Gilbert, R.
    Goldstein, D. P.
    Halmos, G. B.
    Witjes, M. J. H.
    Gietema, J. A.
    O'Sullivan, B.
    Langendijk, J. A.
    Siu, L. L.
    Hansen, A. R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S577 - S577